Electromed, Inc. (ELMD)
Stock Price:
$9.12 USD
-0.13 (-1.41%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
78.44M |
| Revenue (ttm) |
32.47M |
| Net Income (ttm) |
4.16M |
| Shares Out |
8.60M |
| EPS (ttm) |
0.47 |
| PE Ratio |
19.40 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$9.12 |
| Previous Close |
$9.25 |
| Change ($) |
-0.13 |
| Change (%) |
-1.41% |
| Day's Open |
9.37 |
| Day's Range |
9.12 - 9.40 |
| Day's Volume |
37,026 |
| 52-Week Range |
6.61 - 19.73 |
More Stats
| Market Cap |
78.44M |
| Enterprise Value |
67.96M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
8.60M |
| Float |
6.73M |
| EPS (basic) |
0.50 |
| EPS (diluted) |
0.47 |
| FCF / Share |
0.40 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
5.15% |
| FCF Yield |
4.27% |
| Payout Ratio |
n/a |
| Shares Short |
331,129 |
| Short Ratio |
2.83 |
| Short % of Float |
4.92% |
| Beta |
0.30 |
| PE Ratio |
19.40 |
| Forward PE |
n/a |
| P/FCF Ratio |
23.40 |
| PS Ratio |
2.42 |
| PB Ratio |
2.63 |
| Revenue |
32.47M |
| Operating Income |
5.12M |
| Net Income |
4.16M |
| Free Cash Flow |
3.35M |
| Net Cash |
10.48M |
| Net Cash / Share |
1.22 |
| Gross Margin |
77.61% |
| Operating Margin |
15.76% |
| Profit Margin |
12.80% |
| FCF Margin |
10.32% |
| ROA |
8.39% |
| ROE |
14.87% |
| ROIC |
27.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
19.0
Current: $9.12
High
19.0
Target: 19.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 32.47 | 31.30 | 28.31 | 25.86 | 22.99 | 19.41 | 15.49 | 15.10 | 19.52 | 19.00 |
| Revenue Growth | 3.74% | 10.57% | 9.46% | 12.48% | 18.46% | 25.31% | 2.54% | -22.64% | 2.74% | - |
| Gross Profit | 25.20 | 23.85 | 21.77 | 20.57 | 17.88 | 13.60 | 10.63 | 10.45 | 14.15 | 13.78 |
| Operating Income | 5.12 | 2.83 | 2.71 | 3.57 | 3.11 | 1.31 | -0.74 | -1.83 | 0.61 | 1.87 |
| Net Income | 4.16 | 1.98 | 1.83 | 2.23 | 2.21 | 1.09 | -1.29 | -1.33 | 0.19 | 1.06 |
| Shares Outstanding | 8.40 | 8.31 | 8.21 | 8.17 | 8.14 | 8.12 | 8.11 | 8.11 | 8.11 | 7.82 |
| Earnings Per Share | 0.47 | 0.23 | 0.21 | 0.26 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.13 |
| EPS Growth | 104.35% | 9.52% | -19.23% | -3.7% | 107.69% | - | - | - | -84.62% | - |
| Operating Cash Flow | 4.20 | 2.59 | 2.44 | 1.19 | 2.17 | 2.78 | 2.07 | 1.88 | -1.17 | -1.42 |
| Capital Expenditures | -0.84 | -1.33 | -0.53 | -0.62 | -0.53 | -0.52 | -0.90 | -1.02 | -0.79 | -0.45 |
| Free Cash Flow | 3.35 | 1.26 | 1.92 | 0.57 | 1.63 | 2.26 | 1.17 | 0.86 | -1.96 | -1.87 |
| Cash & Equivalents | 10.48 | 7.81 | 7.46 | 5.57 | 5.12 | 3.60 | 1.50 | 0.50 | 1.70 | 4.09 |
| Total Debt | - | - | 1.10 | 1.15 | 1.19 | 1.25 | 1.30 | 1.39 | 3.41 | 3.79 |
| Net Cash / Debt | 10.48 | 7.81 | 6.35 | 4.43 | 3.93 | 2.35 | 0.21 | -0.89 | -1.71 | 0.30 |
| Assets | 33.24 | 29.40 | 27.39 | 23.06 | 20.58 | 17.41 | 15.79 | 17.56 | 20.92 | 20.87 |
| Liabilities | 3.00 | 3.67 | 4.80 | 3.99 | 4.22 | 3.48 | 3.07 | 3.63 | 5.84 | 6.16 |
| Book Value | 30.25 | 25.73 | 22.59 | 19.07 | 16.36 | 13.92 | 12.72 | 13.93 | 15.08 | 14.71 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Electromed, Inc. |
| Country |
United States |
| Employees |
120 |
| CEO |
Kathleen S. Skarvan |
Stock Information
| Ticker Symbol |
ELMD |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NYSEAMERICAN: ELMD |
| IPO Date |
August 13, 2010 |
Description
Electromed develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of all ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was founded in 1992 and is headquartered in New Prague, Minnesota.